NF-κB in pancreatic cancer: Its key role in chemoresistance
Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Li, Quanxiao [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome - Hao, Lijun ELSEVIER, 2015, an international journal providing a forum for original and pertinent contributions in cancer research, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:421 ; year:2018 ; day:1 ; month:05 ; pages:127-134 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.canlet.2018.02.011 |
|---|
| Katalog-ID: |
ELV042206804 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042206804 | ||
| 003 | DE-627 | ||
| 005 | 20230626000839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2018.02.011 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000158A.pica |
| 035 | |a (DE-627)ELV042206804 | ||
| 035 | |a (ELSEVIER)S0304-3835(18)30138-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 | |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Li, Quanxiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NF-κB in pancreatic cancer: Its key role in chemoresistance |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. | ||
| 520 | |a Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. | ||
| 650 | 7 | |a NF-κB |2 Elsevier | |
| 650 | 7 | |a Chemotherapy |2 Elsevier | |
| 650 | 7 | |a Pancreatic cancer |2 Elsevier | |
| 650 | 7 | |a Chemoresistance |2 Elsevier | |
| 700 | 1 | |a Yang, Gang |4 oth | |
| 700 | 1 | |a Feng, Mengyu |4 oth | |
| 700 | 1 | |a Zheng, Suli |4 oth | |
| 700 | 1 | |a Cao, Zhe |4 oth | |
| 700 | 1 | |a Qiu, Jiangdong |4 oth | |
| 700 | 1 | |a You, Lei |4 oth | |
| 700 | 1 | |a Zheng, Lianfang |4 oth | |
| 700 | 1 | |a Hu, Ya |4 oth | |
| 700 | 1 | |a Zhang, Taiping |4 oth | |
| 700 | 1 | |a Zhao, Yupei |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Hao, Lijun ELSEVIER |t GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |d 2015 |d an international journal providing a forum for original and pertinent contributions in cancer research |g Amsterdam [u.a.] |w (DE-627)ELV013094742 |
| 773 | 1 | 8 | |g volume:421 |g year:2018 |g day:1 |g month:05 |g pages:127-134 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.canlet.2018.02.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 421 |j 2018 |b 1 |c 0501 |h 127-134 |g 8 | ||
| 953 | |2 045F |a 570 | ||
| author_variant |
q l ql |
|---|---|
| matchkey_str |
liquanxiaoyanggangfengmengyuzhengsulicao:2018----:fipnraicneiserlice |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
51.00 51.32 |
| publishDate |
2018 |
| allfields |
10.1016/j.canlet.2018.02.011 doi GBV00000000000158A.pica (DE-627)ELV042206804 (ELSEVIER)S0304-3835(18)30138-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Li, Quanxiao verfasserin aut NF-κB in pancreatic cancer: Its key role in chemoresistance 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance Elsevier Yang, Gang oth Feng, Mengyu oth Zheng, Suli oth Cao, Zhe oth Qiu, Jiangdong oth You, Lei oth Zheng, Lianfang oth Hu, Ya oth Zhang, Taiping oth Zhao, Yupei oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:421 year:2018 day:1 month:05 pages:127-134 extent:8 https://doi.org/10.1016/j.canlet.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 421 2018 1 0501 127-134 8 045F 570 |
| spelling |
10.1016/j.canlet.2018.02.011 doi GBV00000000000158A.pica (DE-627)ELV042206804 (ELSEVIER)S0304-3835(18)30138-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Li, Quanxiao verfasserin aut NF-κB in pancreatic cancer: Its key role in chemoresistance 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance Elsevier Yang, Gang oth Feng, Mengyu oth Zheng, Suli oth Cao, Zhe oth Qiu, Jiangdong oth You, Lei oth Zheng, Lianfang oth Hu, Ya oth Zhang, Taiping oth Zhao, Yupei oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:421 year:2018 day:1 month:05 pages:127-134 extent:8 https://doi.org/10.1016/j.canlet.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 421 2018 1 0501 127-134 8 045F 570 |
| allfields_unstemmed |
10.1016/j.canlet.2018.02.011 doi GBV00000000000158A.pica (DE-627)ELV042206804 (ELSEVIER)S0304-3835(18)30138-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Li, Quanxiao verfasserin aut NF-κB in pancreatic cancer: Its key role in chemoresistance 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance Elsevier Yang, Gang oth Feng, Mengyu oth Zheng, Suli oth Cao, Zhe oth Qiu, Jiangdong oth You, Lei oth Zheng, Lianfang oth Hu, Ya oth Zhang, Taiping oth Zhao, Yupei oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:421 year:2018 day:1 month:05 pages:127-134 extent:8 https://doi.org/10.1016/j.canlet.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 421 2018 1 0501 127-134 8 045F 570 |
| allfieldsGer |
10.1016/j.canlet.2018.02.011 doi GBV00000000000158A.pica (DE-627)ELV042206804 (ELSEVIER)S0304-3835(18)30138-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Li, Quanxiao verfasserin aut NF-κB in pancreatic cancer: Its key role in chemoresistance 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance Elsevier Yang, Gang oth Feng, Mengyu oth Zheng, Suli oth Cao, Zhe oth Qiu, Jiangdong oth You, Lei oth Zheng, Lianfang oth Hu, Ya oth Zhang, Taiping oth Zhao, Yupei oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:421 year:2018 day:1 month:05 pages:127-134 extent:8 https://doi.org/10.1016/j.canlet.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 421 2018 1 0501 127-134 8 045F 570 |
| allfieldsSound |
10.1016/j.canlet.2018.02.011 doi GBV00000000000158A.pica (DE-627)ELV042206804 (ELSEVIER)S0304-3835(18)30138-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Li, Quanxiao verfasserin aut NF-κB in pancreatic cancer: Its key role in chemoresistance 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance Elsevier Yang, Gang oth Feng, Mengyu oth Zheng, Suli oth Cao, Zhe oth Qiu, Jiangdong oth You, Lei oth Zheng, Lianfang oth Hu, Ya oth Zhang, Taiping oth Zhao, Yupei oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:421 year:2018 day:1 month:05 pages:127-134 extent:8 https://doi.org/10.1016/j.canlet.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 421 2018 1 0501 127-134 8 045F 570 |
| language |
English |
| source |
Enthalten in GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome Amsterdam [u.a.] volume:421 year:2018 day:1 month:05 pages:127-134 extent:8 |
| sourceStr |
Enthalten in GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome Amsterdam [u.a.] volume:421 year:2018 day:1 month:05 pages:127-134 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| topic_facet |
NF-κB Chemotherapy Pancreatic cancer Chemoresistance |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| authorswithroles_txt_mv |
Li, Quanxiao @@aut@@ Yang, Gang @@oth@@ Feng, Mengyu @@oth@@ Zheng, Suli @@oth@@ Cao, Zhe @@oth@@ Qiu, Jiangdong @@oth@@ You, Lei @@oth@@ Zheng, Lianfang @@oth@@ Hu, Ya @@oth@@ Zhang, Taiping @@oth@@ Zhao, Yupei @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013094742 |
| dewey-sort |
3570 |
| id |
ELV042206804 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042206804</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626000839.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.canlet.2018.02.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000158A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042206804</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0304-3835(18)30138-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, Quanxiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">NF-κB in pancreatic cancer: Its key role in chemoresistance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NF-κB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pancreatic cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemoresistance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Gang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Feng, Mengyu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zheng, Suli</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cao, Zhe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qiu, Jiangdong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">You, Lei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zheng, Lianfang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Ya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Taiping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhao, Yupei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Hao, Lijun ELSEVIER</subfield><subfield code="t">GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome</subfield><subfield code="d">2015</subfield><subfield code="d">an international journal providing a forum for original and pertinent contributions in cancer research</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013094742</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:421</subfield><subfield code="g">year:2018</subfield><subfield code="g">day:1</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:127-134</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.canlet.2018.02.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">421</subfield><subfield code="j">2018</subfield><subfield code="b">1</subfield><subfield code="c">0501</subfield><subfield code="h">127-134</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| author |
Li, Quanxiao |
| spellingShingle |
Li, Quanxiao ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance NF-κB in pancreatic cancer: Its key role in chemoresistance |
| authorStr |
Li, Quanxiao |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013094742 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 610 - Medicine & health 600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl NF-κB in pancreatic cancer: Its key role in chemoresistance NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance Elsevier |
| topic |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance |
| topic_unstemmed |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance |
| topic_browse |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier NF-κB Elsevier Chemotherapy Elsevier Pancreatic cancer Elsevier Chemoresistance |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
g y gy m f mf s z sz z c zc j q jq l y ly l z lz y h yh t z tz y z yz |
| hierarchy_parent_title |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| hierarchy_parent_id |
ELV013094742 |
| dewey-tens |
570 - Life sciences; biology 610 - Medicine & health 600 - Technology 690 - Building & construction |
| hierarchy_top_title |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013094742 |
| title |
NF-κB in pancreatic cancer: Its key role in chemoresistance |
| ctrlnum |
(DE-627)ELV042206804 (ELSEVIER)S0304-3835(18)30138-1 |
| title_full |
NF-κB in pancreatic cancer: Its key role in chemoresistance |
| author_sort |
Li, Quanxiao |
| journal |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| journalStr |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
127 |
| author_browse |
Li, Quanxiao |
| container_volume |
421 |
| physical |
8 |
| class |
570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Li, Quanxiao |
| doi_str_mv |
10.1016/j.canlet.2018.02.011 |
| dewey-full |
570 610 600 690 |
| title_sort |
nf-κb in pancreatic cancer: its key role in chemoresistance |
| title_auth |
NF-κB in pancreatic cancer: Its key role in chemoresistance |
| abstract |
Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. |
| abstractGer |
Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. |
| abstract_unstemmed |
Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 |
| title_short |
NF-κB in pancreatic cancer: Its key role in chemoresistance |
| url |
https://doi.org/10.1016/j.canlet.2018.02.011 |
| remote_bool |
true |
| author2 |
Yang, Gang Feng, Mengyu Zheng, Suli Cao, Zhe Qiu, Jiangdong You, Lei Zheng, Lianfang Hu, Ya Zhang, Taiping Zhao, Yupei |
| author2Str |
Yang, Gang Feng, Mengyu Zheng, Suli Cao, Zhe Qiu, Jiangdong You, Lei Zheng, Lianfang Hu, Ya Zhang, Taiping Zhao, Yupei |
| ppnlink |
ELV013094742 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.canlet.2018.02.011 |
| up_date |
2024-07-06T22:11:49.702Z |
| _version_ |
1803869392421781504 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042206804</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626000839.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.canlet.2018.02.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000158A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042206804</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0304-3835(18)30138-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, Quanxiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">NF-κB in pancreatic cancer: Its key role in chemoresistance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-κB inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-κB signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NF-κB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pancreatic cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemoresistance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Gang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Feng, Mengyu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zheng, Suli</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cao, Zhe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qiu, Jiangdong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">You, Lei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zheng, Lianfang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Ya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Taiping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhao, Yupei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Hao, Lijun ELSEVIER</subfield><subfield code="t">GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome</subfield><subfield code="d">2015</subfield><subfield code="d">an international journal providing a forum for original and pertinent contributions in cancer research</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013094742</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:421</subfield><subfield code="g">year:2018</subfield><subfield code="g">day:1</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:127-134</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.canlet.2018.02.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">421</subfield><subfield code="j">2018</subfield><subfield code="b">1</subfield><subfield code="c">0501</subfield><subfield code="h">127-134</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| score |
7.3984118 |